ClinicalTrials.gg
CompletedNCT05238012XTREMEUpdated May 21, 2024

Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

A Phase 4 interventional study of Xuezhikang Capsule and Atorvastatin Calcium Tablets in Metabolism Disorder, Lipid and Metabolism Disorder, Glucose, sponsored by Heart Health Research Center. Completed at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Primary conditionDyslipidemiasRegistry: Lipid Metabolism DisordersReclassifiedWhy we changed it
Registry
Lipid Metabolism Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dyslipidemias
Why
  1. The study's title name Dyslipidemias, a narrower term within Lipid Metabolism Disorders.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Heart Health Research Center · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Dyslipidemias with a site in China — 23 open to participants now, 33 under way, 10 of them phase 3. Dyslipidemias · China.

Enrollment
20th of 58
392 · median 210
Started
2022
with 3 others
Phase 4
12 of 75
none open now
Registered
40th of 75
by date

Among the 75 studies in Dyslipidemias with a site in China, this one is the 20th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2022, is one of 12 in phase 4, and was the 40th registered.

Dyslipidemias

1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

23 of the 75 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Dyslipidemias with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of treatment in dyslipidemia patients with prediabetes

Read the detailed description

Up to now, there is no published RCTs to compare the impact of XZK and statins on glucose metabolism in Prediabetes with dyslipidemia. However, systematic reviews of several large observational studies have recently found statin treatment is associated with a modest increase in HbA1c in patients with T2DM. In these patients, the mean difference of HbA1c increased by 0.17% (95% CI 0.07, 0.27) compared with the blanking control group[7]. For instance, Atorvastatin 20mg is widely used medium intensity statin in clinical practice, but a cohort study based on a database of Korea populations reported that the use of low dose Atorvastatin 10-20mg tended to be a risk factor for onset diabetes (NODM) in Asians[8]. Meanwhile, a small RCT reported that HbA1c level was increased from 6.1% to 6.5% after Atorvastatin 20mg/d treatment for 2 months[9]. The long-term administration of statins might increase the risk of NODM approximately 10%-12%[10]. In short, a diabetogenic role of statins has been demonstrated both from randomized trials and meta-analyses, and risk factors include high dose, prolonged exposure, old age, prediabetic state and metabolic syndrome[11, 12]. In consideration of prediabetes, including IFG, IGT, or A1C 5.7-6.4%, will be further increased the risk of development diabetes mellitus, and the prevalence was 35.7% in China, we choose the patients in Prediabetes with dyslipidemia in our study[4].

XZK, a partially purified red yeast rice (RYR) under controlled pharmaceutical manufacturing conditions, contains a family of naturally occurring statins (monacolins)-most prominently monacolin K, which is identical to the lipid- lowering therapy lovastatin (Mevacor)[13]. In a meta-analysis, after compared the XZK treatment group showed significant lowering LDL-C effect compared with basic therapy groups. [14] Xuezhikang in the China Coronary Secondary Prevention Study trial(CCSPS) has shown that XZK significantly reduced the levels of TC, TG and LDL-C and increased that of HDL-C in patients with hyperlipidemia after 1200mg/d treatment for 8 weeks, among which TC decreased by 23.0%[15]. Furthermore, a retrospective cohort study that used Taiwan's National Health Insurance data on 34,504 persons with a RYR prescription in 2010-2014, found that a lower risk of incident diabetes when compared to lovastatin cohort (HR:0.46, 95% CI 0.43-0.50)[16]. Why XZK can lower the risk of incident diabetes compared to other statins? A variety of mechanisms have been elucidated. As main components in XZK, n-3 polyunsaturated fatty acid(PUFAs) can regulate the activity of key transcription factors to regulate gene expression in lipid metabolism and improve insulin sensitivity of type 2 diabetes mellitus to prevent diabetic complications. Six weeks of supplementation with n-3 PUFAs reduced the postprandial decrease in macrovascular function and meanwhile improved postprandial microvascular function[17]. Moreover, it was reported that magnesium deficiency can lead to the reduction of insulin sensitivity and affect the stability of glucose metabolism. Thus, increasing the intake of magnesium plays an important role in the prevention of noninsulin- dependent diabetes mellitus and its complications. Moreover, selenium reduces the production of oxygen free radicals in the body by glutathione peroxidase to prevent further oxidative damage in the body and the insulin A, B between the two peptide chains for ensuring the complete molecule structure and function of insulin to play a role in lowering blood glucose. In addition, selenium also has inhibitory effects on complications of diabetes such as osteoporosis and retinopathy.

In addition, XZK has been proved to contain multiple active ingredients which leads to unique MOA and multiple benefits[13]. It is composed of 13 kinds of natural statins, unsaturated fatty acids, ergosterol, amino acids, flavonoids, alkaloid, trace elements, and other substances, and thus could be regarded as a natural lipid lowering polypill[14]. All the above-mentioned components might be involved in the mechanism of XZK to multiple benefits such as antiatherosclerosis, liver protection, anticancer, neural regulation and protection, and kidney protection effects[13]. Previous animal and cell experiments have shown that XZK can also activate the PPARα pathway and up-regulate apolipoprotein A5 (apolipoprotein A5 is the key regulator of TG metabolism) to achieve higher TG reduction when it reduces LDL-C by the same extent as simvastatin[18]. It is speculated that non-statin elements within XZK may play a synergistic role in regulating blood lipids and inhibiting the synthesis of triglycerides. The China Coronary Secondary Prevention Study (CCSPS) and other clinical studies confirmed that XZK capsules reduce lipid and significantly reduce the overall mortality of patients with coronary heart disease, the incidence of cardiovascular events. According to Chinese guidelines for the management of dyslipidemia in adults of 2016 revision, XZK amongst other statins are recommended for the first-line treatment of cholesterol controlling. Meanwhile, XZK 1200mg/d and Atorvastatin 20mg/d are medium intensity statins recommended in guideline[3]. therefore, we choose Atorvastatin 20mg/d as control drug in our research.

Physicians faced with a dyslipidemia patient with prediabetes often use statins therapy due to perceived efficacy. However, XZK is a promising option in this patient group due to their significantly lower risk of dys-glycaemia without compromising efficacy for lowering lipids in hyperlipidemia. Establishing comparable recurrent NODM rates in individuals with previous Prediabetes state would result in superior DM prevention for these patients.

03

Conditions studied

  • Metabolism Disorder, Lipid
  • Metabolism Disorder, Glucose

Keywords

  • Dyslipidemia
  • Prediabetes
04

In context

Dyslipidemias Reclassified

1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

This study's enrollment of 392 is above the median of 100 across 988 interventional studies indexed under Dyslipidemias.

Browse Dyslipidemias studies →

Lead sponsor

Heart Health Research Center is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Compared within Dyslipidemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lipid Metabolism Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Written provided
    1. Age ≥40 years
  • 3 Diagnosed Prediabetes, meeting one of the following conditions: ü Impaired fasting glucose (IFG): 5.6 mmol/L ≤ FPG \<7.0 mmol/L ; ü 5.7-6.4% (39-47 mmol/mol)
    1. Dyslipidemia meets one of the following conditions: ü Fasting LDL-C ≥3.4mmol/L and\<4.9mmol/L,and TG≤5.6 mmol/L ü Fasting non-HDL-C ≥4.1mmol/L and \< 5.7 mmol/L , and TG≤5.6 mmol/L
    1. Completed one-week Patient diary, recorded at least 5 days in a week.

Exclusion criteria

Exclusion Criteria:

    1. Patient with proven or documented atherosclerotic cardiovascular disease (ASCVD), including acute coronary syndrome (ACS), history of myocardial infarction (MI), stable or unstable angina pectoris, coronary or other revascularization, ischemic stroke, and peripheral vascular disease (PAD), etc.
  • 2.Diagnosed diabetes According to 2021 the American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" FPG≥126mg/dL(7.0mmol/L). A know 2-hPG≥200mg/dL(11.1mmol/L)duringOGTT. ≥6.5%(48mmol/mol). In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).
    1. Patientswithanylipidloweringdrugsintheprevious3months,includingbut not limited to statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, nicotinic acid, fibric acid derivatives, fibrates, other traditional Chinese medicine and n-3 fatty acids.
  • 4.Patientswithanyantidiabeticdrugs.
  • 5.ContraindicationstoXZKorAtorvastatin: Allergic to XZK or Atorvastatin. Pregnancy or breastfeeding
  • 6.Uncontrolled hypertension (systolic blood pressure ≥180 mm Hg and/ or diastolic blood pressure ≥110 mm Hg) at screening.
  • 7.Active liver disease or hepatic dysfunction, including continuously elevated liver transaminase due to unknown causes. Abnormal liver function test at baseline ( or AST >3×).
    1. Knownrenaldysfunctionorelevatedserumcreatininelevelsatbaseline(with an ≤60 mL/min/1.73 m2).
  • 9.Otherendocrinediseasesthatmightinfluencethelevelsoflipidorlipoprotein, such as hypothyroidism.
  • 10.Patient has participated in clinical trials of other drugs in the past three months.
  • 11.Previous statin treatment causes creatine kinase (CK) increased 10 times, or myalgia myopathy (muscle pain or muscle weakness, accompanied by Creatine phosphokinase (CK) exceeds 10 times the ULN)
  • 12.Estimated \< 6 months at the time of enrollment
  • 13.Abuse of alcohol, or history of alcohol abuse.
  • 14.Close affiliation with the investigators, e.g., a close relative for the investigator, dependent person (e.g., employee or student of the investigators)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    Xuezhikang Capsule

    Experimental drug: Xuezhikang Capsule, specification: 300mg / capsule.

    Drug: Xuezhikang Capsule

  • Active comparator
    Atorvastatin Calcium Tablets

    Control drug: Atorvastatin Calcium Tablets, specification: 20mg / tablet.

    Drug: Atorvastatin Calcium Tablets

Interventions

  • DrugXuezhikangStudies of XuezhikangXuezhikang pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;

07

What researchers measure

Primary outcomes

  1. HbA1c levels

    To determine whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels from baseline to 24 weeks in dyslipidemia patients with prediabetes.

    Time frame: 24 weeks

Secondary outcomes

  1. Fasting blood glucose(FBG),

    The change value of FBG from baseline to 24 Weeks or before antidiabetic therapy initiation within 24 weeks.

    Time frame: 24 weeks

  2. Post prandial glucose(PPG) 2h

    The change value of PPG 2h from baseline to 24 Weeks or before antidiabetic therapy initiation within 24 weeks.

    Time frame: 24 weeks

  3. HOMA-IR

    The change value of HOMA-IR from baseline to 24 Weeks or before antidiabetic therapy initiation within 24 weeks.

    Time frame: 24 weeks

  4. LDL-C levels

    The percentage change of LDL-C levels from baseline to 24 Weeks or before antidiabetic therapy initiation within 24 weeks.

    Time frame: 24 weeks

  5. non HDL-C levels

    The percentage change of non HDL-C levels from baseline to 24 Weeks or before antidiabetic therapy initiation within 24 weeks.

    Time frame: 24 weeks

  6. HbA1c levels

    The change value of HbA1c levels from baseline to 12 Weeks or before antidiabetic therapy initiation within 12 weeks.

    Time frame: 12 Weeks

  7. Fasting blood glucose(FBG)

    The change value of FBG from baseline to 12 Weeks or before antidiabetic therapy initiation within 12 weeks.

    Time frame: 12 weeks

  8. Post prandial glucose(PPG) 2h

    The change value of PPG 2h from baseline to 12 Weeks or before antidiabetic therapy initiation within 12 weeks.

    Time frame: 12 weeks

  9. HOMA-IR

    The change value of HOMA-IR from baseline to 12 Weeks or before antidiabetic therapy initiation within 12 weeks.

    Time frame: 12 weeks

  10. LDL-C levels

    The percentage change of LDL-C levels from baseline to 12 weeks or before antidiabetic therapy initiation within 12 weeks.

    Time frame: 12 weeks

  11. non HDL-C levels

    The percentage change of non HDL-C levels from baseline to 24 Weeks or before antidiabetic therapy initiation within 12 weeks.

    Time frame: 12 weeks

08

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Apr 2024, 20 months.

Of 37 phase 4 interventional studies under Dyslipidemias, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 40. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2022
First posted
Feb 14, 2022
StartActual
Aug 2, 2022
Primary completionActual
Apr 2, 2024
CompletionActual
Apr 2, 2024
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05238012
Lead sponsor
Heart Health Research Center
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Feb 14, 2022
Start date
Aug 2, 2022
Primary completion
Apr 2, 2024
Completion
Apr 2, 2024
Last update
May 21, 2024

Study contacts

Changsheng Ma, MD
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xuezhikang

Start the discussion